Perioperative and prognostic implication of albumin-bilirubin-TNM score in Child-Pugh class A hepatocellular carcinoma

Fuminori Sonohara1 | Suguru Yamada1 | Nobutake Tanaka1 | Masaya Suenaga1 | Hideki Takami1 | Masamichi Hayashi1 | Yukiko Niwa1 | Hiroyuki Sugimoto1,2 | Norifumi Hattori1 | Mitsuro Kanda1 | Chie Tanaka1 | Daisuke Kobayashi1 | Goro Nakayama1 | Masahiko Koike1 | Michitaka Fujiwara1 | Yasuhiro Kodera1,2

1Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
2Department of Surgery, Komaki City Hospital, Komaki, Japan

Correspondence
Suguru Yamada, Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan. Email: suguru@med.nagoya-u.ac.jp

Abstract

Background and Aim: A reliable classification for predicting postoperative prognosis and perioperative risk of hepatocellular carcinoma (HCC) patients is required to make a precise decision for HCC treatment. In the present study, we assessed the perioperative and prognostic importance of indocyanine green (ICG) testing, tumor-node-metastasis (TNM) stage, albumin-bilirubin (ALBI) grade, and ALBI-TNM (ALBI-T) score using consecutive resected HCC cases.

Methods: Between 1998 and 2011, 273 consecutive patients who underwent primary and curative hepatectomy for HCC were identified. Among these 273 cases, 235 Child-Pugh class A patients were enrolled in the present study.

Results: Correlation analysis showed that the value of linear predictor for ALBI grade was significantly correlated with ICG 15-minute retention rates ($r = 0.51$, $P < 0.0001$). Survival analysis for both recurrence-free survival (RFS) and overall survival (OS) showed there were significant differences between the two groups stratified by stage or ALBI-T score (stage, RFS: $P = 0.01$, OS: $P = 0.003$; ALBI-T, RFS: $P < 0.0001$, OS: $P < 0.0001$). In addition, Cox proportional hazard model identified ALBI-T score was a significant predictor for both RFS and OS (RFS, $P = 0.001$; OS, $P = 0.004$). Furthermore, ALBI-T score could predict perioperative risk in hepatectomy such as longer operation time and excessive intraoperative blood loss.

Conclusions: This study showed a robust association of ALBI-T score with postoperative HCC patient survival and perioperative risk in hepatectomy. ALBI-T score can be used as a simple and powerful tool for assessing HCC patients with further study.

KEYWORDS

ALBI-TNM score, albumin-bilirubin grade, hepatectomy, hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a lethal disease and the second leading cause of cancer death worldwide. For curative treatment of HCC, hepatectomy (hepatic resection) is a major and desirable strategy. However, even after curative hepatectomy, 80% of patients develop HCC recurrence in the remnant liver and 50% die within 5 years. Hetero chronological multiple HCC occurrences are generally associated with background hepatitis caused by virus, alcohol, and non-alcoholic fatty liver disease whereas intrahepatic tumor metastasis is mainly attributed to invasiveness of primary loci and relatively early recurrence. According to these two types of hepatic recurrence, both background liver status and tumor factor of HCC should be considered to make a precise decision for HCC treatment.

Currently, the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) tumor-node-metastasis (TNM) staging system is commonly used for evaluating pretreatment tumor status, and Child-Pugh (CP) classification is applied for evaluating background liver status. However, as previously mentioned, CP classification and the integrated scoring system using CP classification have several limitations as a result of including subjective values such as grading of ascites and hepatic encephalopathy. Indocyanine green (ICG) testing is usually carried out prior to HCC treatment for assessing background liver status especially in Asian countries and in several institutes in Europe. Although ICG testing well reflects the liver function, this examination requires well-organized preparation to obtain an accurate result such as pre-examination bed-rest whether or not using an ICG clearance meter that does not require multiple blood sampling. Hence, a simple and accurate way to evaluate both tumor and background liver status of HCC prior to treatment has been strongly desired.

Lately, albumin-bilirubin (ALBI) grade and ALBI-TNM (ALBI-T) score have attracted clinicians’ attention as more convenient and precise methods to evaluate HCC and background liver. Although there are some important studies showing the prognostic impact of ALBI grade and ALBI-T score on HCC treatment, their actual significance to HCC surgery is still being considered. In the present study, we retrospectively assessed the usefulness of ICG testing, TNM stage of the Liver Cancer Study Group of Japan (LCSGJ), ALBI grade, and ALBI-T score to predict HCC prognosis after hepatectomy and to evaluate the risk at hepatectomy by conducting a search of consecutive resected HCC cases from our institute.

2 | METHODS

2.1 | Patients enrolled in the present study

Between January 1998 and December 2012, 273 consecutive patients who underwent curative hepatectomy for HCC at the Department of Gastroenterological Surgery, Nagoya University Hospital (Nagoya, Japan) were identified. The 235 cases identified as CP class A were enrolled in this study. Written informed consent, as required by the Institutional Review Board, was obtained from all patients for use of the anonymized information.

2.2 | Clinical examination and hepatectomy

Preoperative blood examination was carried out 1 or 2 days prior to surgery. Serum albumin (Alb) concentrations, total bilirubin (T-bil), alpha fetoprotein (AFP), hepatitis C virus (HCV) antibody, hepatitis B virus (HBV) surface antigen concentrations and prothrombin time (PT) were preoperatively measured. ICG testing was carried out before surgery with 162 HCC cases (69%), and ICG 15-min retention rates (ICG-R15) were calculated. Indications for surgery and extent of hepatectomy were determined based on the size, number and location of HCC, presence of ascites, serum Alb and T-bil concentrations, PT, computed tomography (CT) findings, and results of the ICG test.

During the hepatectomy, hepatic parenchyma was mainly dissected with a CUSA system (Valley Lab, Boulder, CO, USA) and a VIO soft-coagulation system (ERBE Elektromedizin, Tübingen, Germany) used since 2007. Most patients underwent surgery using the intermittent Pringle maneuver, clamping the portal triad for 15 minutes each at 5-minute intervals. In appropriate cases, the liver hanging maneuver were carried out both respectively and jointly. Resection was defined as curative when all gross tumors were completely removed; cases of incidentally found small lesions suspected to be HCC that were treated by radiofrequency therapy or microwave coagulation therapy during the surgery were regarded as curative cases.

Surgery-related variables included operation time, intraoperative blood loss (IOBL), and requirement for intraoperative blood transfusion. Tumor-related variables included tumor number and size, and postoperative pathological variables (tumor differentiation, serosal invasion, capsule formation, capsule infiltration, septal formation, vascular invasion, bile duct invasion, and surgical margin). Tumors were categorized as well/ moderately or poorly differentiated, whereas the other pathological variables were categorized as positive or negative, as described by the guidelines of the LCSGJ. We used the definition of the Clavien-Dindo classification to assess postoperative ascites, pleural effusion, bile leakage, and surgical site infection and grade IIIa or greater was considered positive. As for postoperative liver failure, we referred to the grading by the International Study Group of Liver Surgery and, in the present study, grade B and C were considered positive.

2.3 | Follow up after surgery

After discharge, patients were followed up once per month for 3 months and every 3 months thereafter. Blood examination, including those for serum AFP and des-gamma-carboxy prothrombin, was carried out at every outpatient care visit, and dynamic contrast-enhanced CT was done every 6 months. Patients with abnormal data
or suspected lesions underwent further examinations, including contrast ultrasonography, magnetic resonance imaging with gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid, CT with hepatic arteriography, and/or positron emission tomography for the diagnosis of HCC recurrence.

### 2.4 Classifications

Albumin-bilirubin score was calculated and patients were classified with the cut-off points as previously reported.\(^{11}\) Linear predictor for ALBI grade was calculated with the following equation: linear predictor (xb) = \((\log_{10} T\text{-bil} \times 0.66) + (\text{Alb} \times −0.085)\), where Tbil is in \(\mu\)mol/L and Alb is in g/L. The cut-off points for ALBI grade were as follows: grade 1, \(xb < −2.60\); grade 2, \(−2.60 < \text{xb} < −1.39\); grade 3, \(−1.39 < \text{xb}\). TNM stage of each patient was defined with General Rules for the Clinical and Pathological Study of Primary Liver Cancer, Nationwide Follow-Up Survey and Clinical Practice Guidelines by LCSGJ.\(^{13}\) T factor for TNM stage of LCSGJ is as shown in Table S1. ALBI-T score was calculated using the following equation: ALBI-T score = ALBI grade + TNM stage of LCSGJ – 2.\(^{12}\)

### 2.5 Statistical analysis

All statistical analyses were carried out using R version 3.4.3 (https://www.r-project.org/). Continuous variables were expressed as medians (ranges) and compared using the Wilcoxon rank-sum test, and categorical variables were compared using the chi-squared test or Fisher’s exact test, as appropriate. Recurrence-free survival (RFS) was defined as the time between the curative resection of HCC and confirmation of recurrence. Overall survival (OS) was defined as the time between the operation and all-cause death. Cox proportional hazards models were used to determine the risk factors associated with RFS and OS. Survival analysis based on the Kaplan-Meier method and log-rank tests was also carried out. The level of statistical significance was set at \(P < 0.05\), which was obtained using two-tailed tests.

### 3 RESULTS

#### 3.1 Patient characteristics

In the present study, 235 CP class A HCC patients were enrolled, as other classes (B and C) of CP classification were rare in the patients who underwent hepatectomy and the class B cases were hypothesized to have worse prognosis than grade A.\(^{19}\) Patient demographic and clinical characteristics are shown in Table 1. Median patient follow-up time for all cases was 44.1 months (range, 0.3–194 months). At the end of the follow-up period, 108 (46%) patients had died, and median duration from time of surgery to death in these cases was 32 months (range, 0.3 to 169 months). The number of patients who died within 90 days of their surgery was nine (3.8%), and there was no case of intraoperative death. Tumor recurrence in remnant liver occurred in 117 patients (81%), and 19 patients (13%) had distant metastasis without hepatic recurrence after surgery. Median time to postoperative recurrence or distant metastasis was 19 months (range, 0-162 months). In nine patients (6%) information on the locations of tumor recurrence was missing.

| TABLE 1 Characteristics of hepatocellular carcinoma patients in the present study (n = 235) |
|---------------------------------|
| Characteristics       | Value            |
| Age (y)               | Median (range)  | 65 (33–84) |
| Gender, n (%) Male : Female | 192 (82) : 43 (18) |
| Viral infection, \(^a\) n (%) | HBV : HCV : HBV + HCV : non-HBV/HCV | 66 (28) : 118 (50) : 4 (2) : 47 (20) |
| Liver damage classification, \(^b\) n (%) | A : B : C | 175 (75) : 31 (13) |
| Albumin (g/dL) Median (range) | 4.0 (2.8–4.9) |
| Total bilirubin (mg/dL) Median (range) | 0.7 (0.2–2.4) |
| PT (%) Median (range) | 89.9 (40.1–138) |
| AFP (ng/mL) Median (range) | 17 (0.8–222 228) |
| Tumor size (cm) Median (range) | 3.5 (0.08–15) |
| Tumor multiplicity Solidity : Multiple | 178 (76) : 57 (24) |
| ICG-R15 (%) Median (range) | 11.4 (1.6–35.2) |
| Stage, \(^c\) n (%) I : II : III : IV | 27 (12) : 122 (53) : 54 (23) : 28 (12) |
| AFP, alpha-fetoprotein; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; ICG-R15, retention rate of indocyanine green 15 min after dosage; n, number; PT, prothrombin time. \(^a\)There are 4 cases without stage information. \(^b\)There are 29 cases without liver damage information. \(^c\)There are 5 cases with both HBV and HCV are included in each type.

Among 235 CP class A HCC patients, 142 (60%) patients were classified as ALBI grade 1 and 93 (40%) patients were grade 2 and there was no patient classified as grade 3. Histogram of ALBI grade based on virus infection is shown in Figure 1B. The most dominant ALBI-T score in patients with HBV was score 2 whereas score 1 was most frequently seen in patients with HCV (Figure 1B). HCC patients without any hepatitis virus had the same proportion of ALBI grade was significantly different between HBV and HCV patients (\(P = 0.007\)). Using ALBI-T score, 231 informative cases with preoperative stage based on the guidelines of the LCSGJ were classified as follows: score 0: 19 (8%), score 1: 79 (34%), score 2: 86 (37%), score 3: 34 (15%), score 4: 13 (6%); and score 5. 0. Histogram of ALBI-T score based on virus infection is shown in Figure 1B. The most dominant ALBI-T score in patients with HBV was score 2 whereas score 1 was most frequently seen in patients with HCV (Figure 1B). HCC patients without any hepatitis virus had the same tendency of distribution in ALBI and ALBI-T as patients with HCV (Figure 1A,B).

Distributions of clinicopathological features in the HCC patients according to ALBI grade and ALBI-T score are shown in Tables S2 and S3. Proportion of patients with ICG-R15 (<15 or >15) was significantly different between ALBI grade 1 and 2.
(P < 0.0001) as well as Alb concentration (<3.5 or ≥3.5, P < 0.0001) and liver damage score (A or B, C, <0.0001, Table S2) defined by presence of ascites, T-bil concentration, Alb concentration, ICG-R15, and PT. As for ALBI-T score, the proportion of patients was significantly different according to gender (P = 0.03), Alb concentration (P = 0.01), number of tumors (multiple or solitary, P < 0.0001), tumor size (<2 or ≥2 cm, P = 0.003), growth form (expansive or infiltrative, P = 0.001), serosal invasion (P = 0.003), vascular invasion (P < 0.0001), and stage (<III or ≥III, P < 0.0001, Table S3).

### 3.3 Association among ALBI grade, ALBI-T score, and ICG-R15

In 154 informative cases with ICG-R15, a significant difference of ICG-R15 value could be identified between ALBI grade 1 and ALBI grade 2 (P < 0.0001, Figure 1C) although there was no significant difference of ICG-R15 between ALBI-T 0,1,2 and ALBI-T 3,4 (P = 0.96, Figure 1D). In addition, correlation analysis showed that the value of a linear predictor for ALBI grade (ALBI xb) and ICG-R15. Red solid line indicates linear regression line, and the greyish area indicates 95% confidence region of linear regression.
significant correlation between ALBI grade and ICG-R15 may be explained as both ALBI grade and ICG-R15 well reflected the background hepatitis status, so both ALBI grade and ICG-R15 had the same direction in CP class A patients.

### 3.4 Hepatocellular carcinoma prognosis stratified by ICG-R15, stage, ALBI grade, and ALBI-T score

First, to carry out a comparative prognostic analysis, the 235 CP class A cases with curative hepatectomy were divided into two groups according to ICG-R15, stage, ALBI grade, and ALBI-T score as follows: ICG-R15 (<15 vs ≥15), stage (I vs II/III/IV), ALBI grade (1 vs 2), and ALBI-T (0, 1, 2 vs 3, 4). Next, survival analysis stratified by ICG-R15, stage, ALBI grade, and ALBI-T score was carried out using Kaplan-Meier analysis (Figures 2, 3). In both RFS and OS, there were significant differences between the two groups stratified by stage or ALBI-T score (stage, RFS, P = 0.01; OS, P = 0.003; ALBI-T, RFS, P < 0.0001; OS, P = 0.0001, Figures 2B, D and 3B, D). ICG-R15 could also stratify the RFS of HCC cases with a statistical significance (P = 0.01, Figure 2A) but there was no significance in OS (P = 0.36, Figure 3A). Furthermore, RFS and OS analysis with the Cox proportional hazard models identified ALBI-T score as a significant predictor for both RFS and OS (RFS, P = 0.001; OS, P = 0.004) as well as virus status (RFS, P = 0.02; OS, P = 0.01), ICG-R15 (RFS, P = 0.003; OS, P = 0.01), liver damage (RFS, P = 0.002; OS, P = 0.005), tumor number (RFS, P = 0.004; OS, P = 0.005), differentiation (RFS, P = 0.02; OS, P = 0.004), serosal invasion (RFS, P < 0.0001; OS, P = 0.002), vascular invasion (RFS, P < 0.0001; OS, P = 0.0002), and stage (RFS, P = 0.02; OS, P = 0.03, Tables 2 and 3). As in our previous report, serosal and vascular invasions that were tumor factors diagnosed with resected specimens were a strong predictor for HCC prognosis. Among the features that can be presurgically obtained and the classifications using presurgical features, ALBI-T score was able to separate CP class A cases into different prognoses both in RFS and OS better than other classifications or clinical features.

### 3.5 Association of ALBI and ALBI-T with perioperative risk in hepatectomy

We also investigated the impact of ICG-R15, stage, ALBI grade, and ALBI-T score in CP class A patients to operation time, IOBL, and rate of transfusion during hepatectomy (Figure 4). ALBI-T score 3, 4

![Figure 2](image-url) Survival analysis stratified by indocyanine green 15 min after dosage (ICG-R15), stage, albumin-bilirubin (ALBI) grade, and albumin-bilirubin-TNM (ALBI-T) score. A. Recurrence-free survival (RFS) analysis stratified by ICG-R15. B. RFS analysis stratified by stage. C, RFS analysis stratified by ALBI. D, RFS analysis stratified by ALBI-T.
showed significantly longer operative time \((P = 0.002, \text{Figure 4D})\) and significantly more IOBL than score 0, 1, 2 \((P = 0.008, \text{Figure 4H})\). Incidence of carrying out blood transfusion during hepatectomy was significantly higher in ALBI grade 2 cases \((32/54\) cases) than in grade 1 \((24/110, P = 0.002)\), whereas there was no significant difference according to ALBI-T \((P = 0.13)\), ICG-R15 \((P = 0.83)\), and stage \((P = 0.17)\). In addition, we assessed major complications after hepatectomy stratified by ICG-R15, stage, ALBI grade, and ALBI-T score (Table S4). According to this analysis, stage was associated with pleural effusion \((P < 0.0001)\); ALBI grade was associated with persistent ascites \((P = 0.002)\); and ALBI-T score was associated with both ascites and pleural effusion \((P = 0.04\) and 0.0003). Consequently, these results indicate that ALBI-T score has a capability of predicting operation time, IOBL, and postoperative complications preoperatively as well as predicting postoperative prognosis.

### 4 DISCUSSION

In this study, we evaluated perioperative clinical importance of ICG-R15, stage, ALBI grade, and ALBI-T score in CP class A patients who underwent hepatectomy for HCC. Because most of the patients who undergo hepatectomy are CP class A, we focused only on CP class A patients in the present study. Our findings suggested that ALBI grade correlates well with ICG-R15 reflecting the background liver function. In addition, ALBI-T score was a robust predictor for both RFS and OS in CP class A patients after hepatectomy. Furthermore, ALBI-T score or ALBI grade was significantly associated with operation time, IOBL, and need for intraoperative transfusion. Consequently, ALBI-T score is capable of assessing the preoperative risk and patients’ prognosis after hepatectomy. Currently, thanks to achievements made by our predecessors, the safety and feasibility of hepatectomy have been greatly improved. However, a report by the National Clinical Database group in Japan showed that the rate of mortality at hepatectomy and at 30 days postoperatively was still 2.3% and 1.3%, respectively, in 2016.\(^{21}\) We believe that even among patients diagnosed with relatively well-preserved hepatic function (CP class A), some might be better off undergoing non-surgical treatment. We believe that precise evaluation prior to surgery is essential to achieve patients’ maximum benefit. Thus, ALBI grade and ALBI-T are potentially capable of contributing to precision treatment for HCC patients.

---

**FIGURE 3** Survival analysis stratified by indocyanine green 15 min after dosage (ICG-R15), stage, albumin-bilirubin (ALBI) grade, and albumin-bilirubin-TNM (ALBI-T).

- **A**, Overall survival (OS) analysis stratified by ICG-R15. **B**, OS analysis stratified by stage.
- **C**, OS analysis stratified by ALBI. **D**, OS analysis stratified by ALBI-T.
A major obstacle for HCC treatment is the high frequency of recurrence even after complete resection or liver transplantation. The poor prognosis and high frequency of HCC recurrence is associated with both tumor factors and background liver status. To deliver a desired precision treatment to HCC patients, estimating the prognosis of patients planning to undergo hepatectomy is essential. Furthermore, hepatectomy has a potential risk of massive bleeding requiring blood transfusion that causes severe complications such as hepatic failure after surgery. To avoid perioperative fatality, evaluating background liver status and developing an appropriate strategy are also crucial. Thus, in terms of the unique aspects of prognosis and operative risk of HCC, we compared ICG-R15, stage, ALBI grade, and ALBI-T score and finally shed light on the superiority of ALBI-T comprising both tumor features and background liver status.

Table 2: Univariate analysis of recurrence-free survival

| Variables                  | 95% CI Low | 95% CI High | P   |
|----------------------------|------------|-------------|-----|
| Age (y)                    | ∆≥65 vs <65 | 1.24        | 0.91 | 1.68 | 0.60 | 0.17 |
| Gender Male vs female      | 0.84       | 0.66        | 1.09 | 0.70 | 0.16 | 0.29 |
| Virus infection HCV vs others | 0.50     | 0.35        | 0.95 | 0.70 | 0.05 | 0.02 |
| Albumin (g/dL) <3.5 vs ≥3.5 | 1.80      | 1.17        | 2.79 | 1.80 | 0.03 | 0.008|
| PT (%) >70 vs ≤70          | 0.75       | 0.66        | 0.95 | 1.57 | 0.16 | 0.74 |
| ICG-R15 (%) ≥15 vs <15     | 0.93       | 0.78        | 1.28 | 0.93 | 0.03 | 0.003|
| Liver cirrhosis (+) vs (−) | 1.14       | 0.84        | 1.56 | 1.28 | 0.09 | 0.07 |
| Liver damage B or C vs A   | 0.89       | 0.64        | 1.28 | 0.89 | 0.03 | 0.002|
| Tumor number Multiple vs solitary | 0.66   | 0.43        | 0.85 | 0.66 | 0.03 | 0.004|
| Tumor size (cm) ≥2 vs <2   | 1.13       | 0.92        | 1.40 | 1.13 | 0.03 | 0.03 |
| AFP (ng/mL) ≥15 vs <15     | 0.93       | 0.78        | 1.28 | 0.93 | 0.03 | 0.003|
| Differentiation Poor vs well/ moderate | 0.52 | 0.30        | 0.92 | 0.60 | 0.03 | 0.005|
| Growth form Infiltrative vs expansive | 0.84 | 0.75        | 0.94 | 0.70 | 0.03 | 0.01 |
| Formation of capsule (−) vs (+) | 1.14   | 0.94        | 1.40 | 0.84 | 0.16 | 0.31 |
| Infiltration to capsule (+) vs (−) | 1.14 | 0.94        | 1.40 | 0.84 | 0.16 | 0.31 |
| Septal formation (−) vs (+) | 0.99       | 0.71        | 1.36 | 0.99 | 0.03 | 0.09 |
| Serosal invasion (−) vs (+) | 1.99       | 1.53        | 2.77 | 1.99 | 0.03 | 0.001|
| Portal vein or hepatic vein invasion (−) vs (+) | 1.99    | 1.43        | 2.77 | 1.99 | 0.03 | 0.001|
| Surgical margin (−) vs (+)  | 1.00       | 0.62        | 1.64 | 1.00 | 0.03 | 0.001|
| Stage III/IV vs I/II       | 1.17       | 1.07        | 1.30 | 1.17 | 0.02 | 0.001|
| ALBI grade 2,3 vs 1        | 1.22       | 0.90        | 1.67 | 1.22 | 0.02 | 0.001|
| ALBI-T score 3,4,5 vs 0,1,2| 1.85       | 1.28        | 2.67 | 1.85 | 0.02 | 0.001|

Table 3: Univariate analysis of overall survival

| Variables                  | 95% CI Low | 95% CI High | P   |
|----------------------------|------------|-------------|-----|
| Age (y)                    | ∆≥65 vs <65 | 1.67        | 1.14 | 2.46 | 0.09 | 0.009|
| Gender Male vs female      | 1.23       | 0.73        | 2.06 | 1.23 | 0.44 | 0.04 |
| Virus infection HCV vs others | 0.61      | 0.41        | 0.90 | 0.61 | 0.03 | 0.01 |
| Albumin (g/dL) <3.5 vs ≥3.5 | 1.68       | 0.98        | 2.87 | 1.68 | 0.06 | 0.00 |
| PT (%) <70 vs ≥70          | 1.26       | 0.66        | 2.39 | 1.26 | 0.48 | 0.48 |
| ICG-R15 (%) ≥15 vs <15     | 1.97       | 1.15        | 3.38 | 1.97 | 0.01 | 0.01 |
| Liver cirrhosis (+) vs (−) | 1.38       | 0.94        | 2.05 | 1.38 | 0.10 | 0.01 |
| Liver damage B or C vs A   | 2.10       | 1.25        | 3.53 | 2.10 | 0.05 | 0.005|
| Tumor number Multiple vs solitary | 0.60   | 0.39        | 0.90 | 0.60 | 0.09 | 0.01 |
| Tumor size (cm) ≥2 vs <2   | 1.73       | 0.90        | 3.33 | 1.73 | 0.10 | 0.10 |
| AFP (ng/mL) ≥15 vs <15     | 1.70       | 1.14        | 2.53 | 1.70 | 0.09 | 0.009|
| Differentiation Poor vs well/ moderate | 0.39 | 0.21        | 0.73 | 0.39 | 0.04 | 0.005|
| Growth form Infiltrative vs expansive | 1.29 | 0.79        | 2.10 | 1.29 | 0.31 | 0.04 |
| Formation of capsule (−) vs (+) | 1.11   | 0.73        | 1.68 | 1.11 | 0.62 | 0.23 |
| Infiltration to capsule (+) vs (−) | 0.98 | 0.67        | 1.44 | 0.98 | 0.62 | 0.43 |
| Septal formation (−) vs (+) | 0.84       | 0.57        | 1.25 | 0.84 | 0.40 | 0.04 |
| Serosal invasion (+) vs (−) | 2.04       | 1.30        | 3.20 | 2.04 | 0.02 | 0.002|
| Portal vein or hepatic vein invasion (+) vs (−) | 2.18   | 1.45        | 3.27 | 2.18 | 0.002|
| Surgical margin (−) vs (+)  | 1.49       | 0.87        | 2.55 | 1.49 | 0.15 | 0.05 |
| Stage III/IV vs I/II       | 1.55       | 1.05        | 2.28 | 1.55 | 0.03 | 0.03 |
| ALBI grade 2,3 vs 1        | 1.40       | 0.95        | 2.06 | 1.40 | 0.06 | 0.06 |
| ALBI-T score 3,4,5 vs 0,1,2| 3.45       | 2.12        | 5.90 | 3.45 | 0.04 | 0.004|

AFP, alpha fetoprotein; ALBI, albumin-bilirubin; ALBI-T, albumin-bilirubin-TNM; CI, confidence interval; HCV, hepatitis C virus; HR, hazard ratio; ICG-R15, indocyanine green 15-min retention rate; PT, prothrombin time; TNM, tumor node metastasis.
pattern: intrahepatic metastasis and multicentric occurrence. Therefore, prognostic classification for HCC should be related to both tumor factor and background liver status.

ALBI grade was originally developed by Johnson et al as a simple predictive model for HCC prognosis incorporating serum T-bil and serum Alb concentrations only. This model can eliminate non-objective factors such as presence of hepatic encephalopathy and ascites used by CP classification. The authors included HCC patients with several treatment modalities and demonstrated that ALBI grade was able to stratify the OS of 525 CP A and B patients who underwent hepatectomy. In addition, Hiraoka et al recently reported that ALBI-T score has a better ability of predicting HCC prognosis than other classifications considering both tumor and background liver status. Consistent with previous reports, in CP class A patients who underwent hepatectomy for HCC, for the first time we showed that ALBI-T score could stratify both RFS and OS more effectively than single ALBI grade, stage, and ICG-R15. Interestingly, ALBI-T score was superior to the LCSGJ staging system in stratification of HCC prognosis. Prognostic analysis in the present study showed that hepatic function assessed by both ICG-R15 and ALBI grade was able to stratify RFS to some extent, but could not stratify OS very well. According to these results, we hypothesized that OS of CP class A patients with resectable HCC is mainly affected by tumor status before the patients suffer from late-stage liver failure or multiple heterochronic recurrences. Thus, ALBI-T score, which is a combination of ALBI grade and LCSGJ staging, could stratify HCC RFS more effectively than single classifications.

Hepatectomy has more potential risks for excessive IOBL than other types of gastrointestinal surgery as a result of anatomy and histology. Post-surgical hepatic failure should always be considered prior to hepatectomy. Tumor factors such as size, vascular invasion, and bile duct invasion may prevent the surgeon from simple resection. Furthermore, in normal soft hepatic tissue, it is much easier to distinguish small vessels in hepatic parenchyma that should be precisely treated than in relatively fibrous hard tissue even if it has not yet reached liver cirrhosis. Thus, background liver status as well as HCC tumor itself should be accurately estimated and classified to minimize the potential risk in hepatectomy and to identify the individual benefit of surgery. The current study showed that ALBI-T score was significantly associated with both operation time and IOBL and that ALBI grade was associated with intraoperative transfusion. With a further validation study, these characteristics of ALBI grade and ALBI-T score could be useful for surgeons preparing for a hepatectomy.

\[\text{FIGURE 4} \text{ Operation time and intraoperative blood loss (IOBL) according to indocyanine green 15 min after dosage (ICG-R15), stage, albumin-bilirubin (ALBI) grade, and albumin-bilirubin-TNM (ALBI-T) score. A, Operation time according to ICG-R15. B, Operation time according to stage. C, Operation time according to ALBI grade. D, Operation time according to ALBI-T. E, IOBL according to ICG-R15. F, IOBL according to stage. G, IOBL according to ALBI. H, IOBL according to ALBI-T.}\]
The present study was able to show a significant association between ALBI-T score and operation time, IOBL, and postoperative prognosis in CP class A patients. However, there are several inherent limitations in this study. First, this study was based on retrospective single-institutional clinical information. The HCC patients enrolled in this study were from Japan only, and it is well known that HCC from different regions has a different etiology and prognosis. In addition, the screening system for HCC in Japan is well established and relatively small HCC can be frequently treated by hepatectomy. Thus, the ALBI established and relatively small HCC can be frequently treated by that HCC from different regions has a different etiology and prognosis in CP class A patients. However, there are several inherent limitations in this study. First, this study was based on retrospective single-institutional clinical information. The HCC patients enrolled in this study were from Japan only, and it is well known that HCC from different regions has a different etiology and prognosis. In addition, the screening system for HCC in Japan is well established and relatively small HCC can be frequently treated by hepatectomy. Thus, the ALBI established and relatively small HCC can be frequently treated by hepatectomy for HCC. ALBI for small hepatocellular carcinoma: a definition and grading by the International Study Group of Liver Surgery (ISGLS). J Gastroenterol Hepatol 2002;17:691–695.

In conclusion, the present study showed robust association of ALBI-T score with perioperative risks of hepatectomy and postoperative patient survival in CP class A patients who underwent hepatectomy for HCC. ALBI-T score is a simple and powerful tool for estimating both patient tumor factor and background liver status simultaneously. With further study, we could use ALBI-T score as a convenient way to assess HCC patients and deliver a more precise treatment to individual HCC patients.

DISCLOSURE

Conflicts of Interest: Authors declare no conflicts of interests for this article.

Author Contributions: Conception and design: FS, SY, HS; Administrative support: VK, SY; Provision of study materials and patients: FS, NT, MS, HT, MH, YN, SY, HS, NH, MK, CT, DK, GN, MK, MF; Collection and assembly of data: FS, NT, SY, HS; Manuscript writing: FS; Final approval of manuscript: all authors.

ORCID

Fuminori Sonohara http://orcid.org/0000-0001-6438-2122
Suguru Yamada http://orcid.org/0000-0001-9912-9119
Chie Tanaka http://orcid.org/0000-0002-7931-8753
Michitaka Fujiwara http://orcid.org/0000-0002-7189-5580
Yasuhiro Kodera http://orcid.org/0000-0002-6173-7474

REFERENCES

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.

2. Rahbari NN, Mehrabi A, Mollberg NM, et al. Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg. 2011;253:453–69.

3. Kobayashi A, Kawasaki S, Miyagawa S, et al. Results of 404 hepatic resections including 80 repeat hepatectomies for hepatocellular carcinoma. Hepatogastroenterology. 2006;53:736–41.

4. Chen MS, Li QJ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;243:321–8.

5. Taura K, Ikai I, Hatano E, Fujii H, Uyama N, Shimahara Y. Implication of frequent local ablative therapy for intrahepatic recurrence in prolonged survival of patients with hepatocellular carcinoma undergoing hepatic resection: an analysis of 610 patients over 16 years old. Ann Surg. 2006;244:265–73.

6. Foner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245–55.

7. Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and date phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38:200–7.

8. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer-Verlag; 2002.

9. Imamura H, Sano K, Sugawara Y, Kokudo N, Makuchii M. Assessment of hepatic reserve for indication of hepatic resection: decision tree incorporating indocyanine green test. J Hepatobiliary Pancreat Surg. 2005;12:16–22.

10. Kubota K, Makuchii M, Kusaka K, et al. Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology. 1997;26:1176–81.

11. Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33:550–8.

12. Hiraoka A, Kumada T, Michitaka K, et al. Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2016;31:1031–6.

13. Liver Cancer Study Group of Japan. General Rules for the Clinical and Pathological Study of Primary Liver Cancer. 3rd English ed. Tokyo: Kanehara & Co., Ltd; 2010.

14. Man K, Fan ST, Ng IOL, Lo CM, Liu CL, Wong J. Prospective evaluation of Pringle maneuver in hepatectomy for liver tumors by a randomized study. Ann Surg. 1997;226:704–11.

15. Belghiti J, Guevara OA, Noun R, Saldinger PF, Kianmanesh R. Liver resectional surgery for hepatic tumors. In: Liver surgery: a new concept of liver segmentation. Kanehara & Co., Ltd; 2010.

16. Takasaki K. Gissonean pedicle transaction method for hepatic resection: a new concept of liver segmentation. J Hepatobiliary Pancreat Surg. 1998;5:286–91.

17. Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2):187–96.

18. Rahbari NN, Garden OJ, Padbury R, et al. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery. 2011;149(5):713–24.

19. Wayne JD, Lauwers GY, Doherty DA, et al. Preoperative predictors of survival after resection of small hepatocellular carcinomas. Ann Surg. 2002;235:722–30.

20. Sonohara F, Nomoto S, Inokawa Y, et al. Serosal invasion strongly associated with recurrence after curative hepatic resection of hepatocellular carcinoma: a retrospective study of 214 consecutive cases. Medicine (Baltimore). 2015;94:e602.

21. Kakeji Y, Takahashi A, Udagawa H, et al. Surgical outcomes in gastrointestinal surgery in Japan: report of National Clinical database 2011-2016. Ann Gastroenterol Surg. 2018;2(1):37–54.
22. Ha TY, Hwang S, Moon DB, et al. Long-term survival analysis of liver transplantation for hepatocellular carcinoma with bile duct tumor thrombus. Transpl Proc. 2014;46:774–7.
23. Poon RTP, Fan ST, Ng IOI, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer. 2000;89:500–7.
24. Shirabe K, Shimada M, Gion T, et al. Postoperative liver failure after major hepatic resection for hepatocellular carcinoma in the modern era with special reference to remnant liver volume. J Am Coll Surg. 1999;188:304–9.
25. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–17.
26. Chevret S, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d’Étude et de Traitemen du Carcinome Hepatocellulaire. J Hepatol. 1999;31:133–41.
27. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology. 1998;28:751–5.
28. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329–38.
29. Leung TW, Tang AM, Zee B, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer. 2002;94:1760–9.
30. Faria SC, Szklaruk J, Kaseb AO, Hassabo HM, Elsayes KM. TNM/Okuda/Barcelona/UNOS/CLIP International Multidisciplinary Classification of Hepatocellular Carcinoma: concepts, perspectives, and radiologic implications. Abdom Imaging. 2014;39:1070–87.
31. de Boer MT, Molenaar IQ, Porte RJ. Impact of blood loss on outcome after liver resection. Dig Surg. 2007;24:259–64.
32. Seyama Y, Yokoda N. Assessment of liver function for safe hepatic resection. Hepatol Res. 2009;39:107–16.
33. Belli G, Fantini C, D’Agostino A, et al. Laparoscopic versus open liver resection for hepatocellular carcinoma in patients with histologically proven cirrhosis: short- and middle-term results. Surg Endosc. 2007;21:2004–11.
34. Blonski W, Kotlyar DS, Forde KA. Non-viral causes of hepatocellular carcinoma. World J Gastroenterol. 2010;16:3603–15.
35. Bellentani S. The epidemiology of non-alcoholic fatty liver disease. Liver Int. 2017;37(Suppl 1):81–4.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Sonohara F, Yamada S, Tanaka N, et al. Perioperative and prognostic implication of albumin-bilirubin-TNM score in Child-Pugh class A hepatocellular carcinoma. Ann Gastroenterol Surg. 2019;3:65–74. https://doi.org/10.1002/ags3.12212